Beta Bionics Reports 38% Revenue Growth to $32M in Q2 2026

Beta Bionics, Inc. reported significant financial performance improvements in its latest quarterly filing, with net sales reaching $32.0 million for the three months ended June 30, 2026, a 38% increase from $23.2 million in the same period last year. For the first half of 2026, net sales totaled $59.6 million, up 46% from $40.9 million in the prior year. The growth was primarily driven by increased sales of single-use products associated with the iLet insulin delivery device, which accounted for 60% of net sales in the second quarter, up from 41% a year earlier. The company also noted a shift in sales channels, with 36% of net sales coming from the Pharmacy Benefit Plan (PBP) channel, compared to 20% in the previous year.

Despite the revenue growth, Beta Bionics reported a net loss of $23.4 million for the second quarter, a 39% increase from a loss of $16.9 million in the same quarter of 2025. For the first half of 2026, the net loss was $45.3 million, slightly improved from a loss of $45.5 million in the prior year. The increase in losses was attributed to higher operating expenses, which rose 37% to $44.5 million in the second quarter, driven by increased research and development, sales and marketing, and general administrative costs. Research and development expenses alone increased by 15% to $10.2 million, reflecting the company's commitment to innovation and product development.

In terms of operational metrics, Beta Bionics has expanded its customer base, with a notable increase in new patient starts. The company has focused on enhancing its sales and marketing efforts, particularly in the PBP channel, which has shown promising growth potential. The iLet device, cleared by the FDA for use in type 1 diabetes, has been well-received, with approximately 69% of new users transitioning from multiple daily injections to the iLet system. The company is also actively pursuing partnerships with major continuous glucose monitor manufacturers to enhance the iLet's functionality.

Looking ahead, Beta Bionics plans to continue investing in its product pipeline, including the development of Mint, a next-generation tubeless insulin patch pump, and a bihormonal system that combines insulin and glucagon delivery. The company anticipates that these innovations will further expand its market reach and improve patient outcomes. Beta Bionics expects to maintain its growth trajectory, supported by its multi-channel coverage strategy and ongoing enhancements to its product offerings. As of June 30, 2026, the company reported cash, cash equivalents, and investments totaling $225.2 million, providing a solid financial foundation for its future initiatives.